FutureChem KRX:220100KOSDAQ
퓨쳐켐 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days17
DART filings, 7 days0
Articles tracked23since Sep 11
In Q2 2026, FutureChem reported revenue of ₩4.3bn, up 17.4% year on year, and an operating loss of ₩3.2bn. FutureChem (퓨쳐켐) appeared in 17 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 23 with 10 articles. The most common catalyst was clinical & approvals (7).
Filing signals Clinical trial filing 4 quarters of losses Screener
FutureChem quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.3bn | +17.4% | −₩3.2bn margin −75.4% | – |
| Q1 2026 | ₩6.4bn | +25.3% | −₩2.2bn margin −34.8% | −₩2.0bn |
| Q4 2025 derived | ₩6.2bn | -1.2% | −₩1.4bn margin −22.9% | – |
| Q3 2025 | ₩3.8bn | -9.4% | −₩2.5bn margin −66.7% | – |
| Q2 2025 | ₩3.6bn | +6.0% | −₩1.9bn margin −52.6% | – |
| Q1 2025 | ₩5.1bn | +47.7% | −₩1.9bn margin −37.4% | −₩2.4bn |
| Q4 2024 derived | ₩6.2bn | +33.3% | −₩2.4bn margin −37.9% | −₩547m |
| Q3 2024 | ₩4.2bn | +24.2% | −₩2.3bn margin −56.0% | −₩3.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
FutureChem top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest FutureChem news Korean headlines
-
Major[종목상담 주식민원처리반] 미국 임상 결과 따른 신약 개발 기대감 고조 '퓨쳐켐'
1 more on this story · 1 outlets
- [종목상담 주식민원처리반] 미국 임상 결과 따른 신약 개발 기대감 고조 '퓨쳐켐'머니투데이 · Oct 26 19:07
-
Major퓨쳐켐 'FC705', 美 임상 2a상서 객관적반응률 38.9%…완전관해 5명
1 more on this story · 1 outlets
- 퓨쳐켐 FC705, 미국 2a상서 객관적반응률 38.9%메디포뉴스 · Oct 23 21:43
-
퓨쳐켐, 17일 무상증자 권리락 발생
2 more on this story · 2 outlets
- 퓨쳐켐, 17일 무상증자 권리락 발생이데일리증권 · Sep 16 17:20
- 퓨쳐켐, 17일 무상증자 권리락 발생이데일리 · Sep 16 17:20